Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
13 studies found for:    matulonis
Show Display Options
Rank Status Study
1 Not yet recruiting Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Pembrolizumab;   Drug: Pegylated Liposomal Doxorubicin (PLD)
2 Recruiting Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Interventions: Drug: BKM120 and Olaparib;   Drug: BYL719 and Olaparib
3 Active, not recruiting Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
4 Completed
Has Results
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Epithelial Cancer;   Stage I Ovarian Epithelial Cancer;   Stage II Ovarian Epithelial Cancer
Intervention: Drug: cediranib maleate
5 Not yet recruiting Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: entinostat;   Drug: avelumab;   Drug: Placebo
6 Completed A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Drug: Active comparator: Niraparib;   Drug: placebo
7 Completed
Has Results
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Bevacizumab;   Drug: Cyclophosphamide
8 Terminated
Has Results
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Mixed Tumor, Mesodermal
Interventions: Drug: Paclitaxel;   Drug: Carboplatin
9 Completed Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Carboplatin;   Drug: Pemetrexed
10 Withdrawn Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Olaparib
11 Terminated GSK1120212+GSK2141795 for Cervical Cancer
Condition: Cervical Cancer
Interventions: Drug: GSK1120212 (trametinib);   Drug: GSK2141795
12 Terminated Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Vorinostat;   Device: Carboplatin;   Drug: Gemcitabine
13 Recruiting First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Condition: FOLR-1 Positive Solid Tumors
Intervention: Drug: IMGN853

Indicates status has not been verified in more than two years